Introduction
Materials and methods
Literature search
Selection criteria
Data extraction
Assessment of study quality
Source | Year | Type of lymphocytes | Country | Number of participant | Duration of follow-up (months) | Clinicopathologic characteristic | Short-term prognosis | Long-term prognosis | Quality score |
---|---|---|---|---|---|---|---|---|---|
Makiko Ono [33] | 2012 | Total types | Japan | 180 | 64.8 | HR, HER-2 | pCR | DFS | 7 |
Sherene Loi [44] | 2013 | Total types | Hungary | 2009 | 96 | – | – | OS, DFS | 5 |
S. Loi [27] | 2014 | Total types | Australia | 1010 | – | G, HR, HER-2 | – | – | 4 |
M. V. Dieci [32] | 2014 | Total types | France | 278 | 76 | G, T, N | – | OS, MFS | 8 |
Rin Yamaguchi [41] | 2011 | Total types | Japan | 68 | – | – | pCR | – | 6 |
Carsten Denkert [17] | 2010 | Total types | Germany | 1058 | – | – | pCR | – | 7 |
Sylvia Adams [40] | 2014 | Total types | USA | 705 | 127 | – | – | OS, DFS | 7 |
Hee Jin Lee [42] | 2013 | Total types | Korea | 175 | – | – | pCR | – | 6 |
Nathan R. West [43] | 2011 | Total types | Canada | 113 | – | – | pCR | – | 6 |
S. Muenst [34] | 2013 | PD-1+
| USA | 660 | 65 | G, T, N, HR, HER-2, Ki67 | – | OS | 7 |
Shenyou Sun [35] | 2013 | PD-1+, Foxp3+
| China | 208 | 72 | G, T, N, HR, HER-2 | – | OS, DFS | 7 |
Chunling Ma [19] | 2012 | CD8+, Foxp3+, γδT | China | 81 | 60 | T, N, HR, HER-2 | – | OS, DFS | 6 |
A. N. Seo [15] | 2013 | CD8+, Foxp3+
| Korea | 153 | – | G, HR, HER-2, Ki67 | – | – | 5 |
Sahar M. A. Mahmoud [36] | 2010 | Foxp3+
| UK | 1445 | 180 | T, N, HR, HER-2 | – | CSS | 6 |
Rafal Matkowski [45] | 2009 | CD8+
| Poland | 88 | 39 | – | – | OS, DFS | 5 |
Shuzhen Liu [38] | 2012 | CD8+
| Canada | 3403 | 65 | G, T, N, HR, HER-2 | – | CSS | 6 |
Sahar M. A. Mahmoud [37] | 2011 | CD8+
| Egypt | 1334 | 127 | G, HR, HER-2 | – | CSS | 6 |
Statistical analysis
Results
Search results and characteristics of eligible studies
Higher value of total TILs was not associated with breast cancer clinicopathological features, but some subtypes may have
Subtype of TILs | Tumor grade (G1–2 vs. G3) | Tumor size (T1 vs. T2–4) | Lymph node status (+ vs. −) | Hormone receptor (+ vs. −) | HER-2 (+ vs. −) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RR (95 % CI) |
I
2 (%) |
P value | RR (95 % CI) |
I
2 (%) |
P value | RR (95 % CI) |
I
2 (%) |
P value | RR (95 % CI) |
I
2 (%) |
P value | RR (95 % CI) |
I
2 (%) |
P value | |
Total TILs | 0.93 (0.77, 1.13) | 0 | 0.46 | – | – | – | – | – | – | 0.48 (0.07, 3.23) | 96 | 0.45 | 0.83 (0.61, 1.12) | 0 | 0.22 |
PD-1+ TILs | 0.63 (0.54, 0.73) | 0 | <0.00001 | 0.72 (0.62, 0.82) | 0 | <0.00001 | 1.76 (1.50, 2.07) | 0 | <0.00001 | 0.75 (0.66, 0.84) | 0 | <0.00001 | 1.53 (1.08, 2.16) | 9 | 0.02 |
Foxp3+ TILs | 0.60 (0.53, 0.68) | 46 | <0.00001 | 0.86 (0.71, 1.03) | 47 | 0.11 | 1.31 (0.94, 1.81) | 65 | 0.11 | 0.81 (0.72, 0.91) | 56 | 0.0004 | 1.95 (1.09, 3.46) | 71 | 0.02 |
CD8+ TILs | 0.97 (0.73, 1.28) | 92 | 0.81 | 0.97 (0.76, 1.24) | 38 | 0.83 | 0.75 (0.33, 169) | 91 | 0.48 | 0.92 (0.84, 1.00) | 55 | 0.06 | 1.30 (1.12, 1.51) | 0 | 0.0006 |